You may be at risk for a liver disease called NASH, and may be eligible for a study of an investigational treatment for this disease. NASH (nonalcoholic steatohepatitis) is caused by a buildup of fat in the liver. If it progresses, it can lead to liver damage or cirrhosis. A research study is being conducted to evaluate the safety and effects on liver fat of two oral investigational medications when used together, or when used singularly, compared to placebo (an inactive substance), for the treatment of NASH. You may be eligible to join this study if you are:
Male, or female of non-childbearing potential, between the ages of 18 and 70, and
Willing to follow a plan of scheduled study visits, lab tests and other study procedures for the duration of the study; up to 19 weeks.
For eligible study participants, all study medication, taken in tablet form, or placebo and study doctor visits will be provided at no cost to you during the study period. Participation in the study is voluntary and you may
withdraw at any time.
$127 per visit, total of up to $1,397 for study completion